NKTR (Nektar Therapeutics) FCF Margin % : -161.30% (As of Jun. 2024)

View and export this data going back to 1994. Start your Free Trial

What is Nektar Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Nektar Therapeutics's Free Cash Flow for the three months ended in Jun. 2024 was $-37.89 Mil. Nektar Therapeutics's Revenue for the three months ended in Jun. 2024 was $23.49 Mil. Therefore, Nektar Therapeutics's FCF Margin % for the quarter that ended in Jun. 2024 was -161.30%.

As of today, Nektar Therapeutics's current FCF Yield % is -80.06%.

The historical rank and industry rank for Nektar Therapeutics's FCF Margin % or its related term are showing as below:

NKTR' s FCF Margin % Range Over the Past 10 Years
Min: -419.65 Med: -142.67 Max: 58.99
Current: -188.25

During the past 13 years, the highest FCF Margin % of Nektar Therapeutics was 58.99%. The lowest was -419.65%. And the median was -142.67%.

NKTR's FCF Margin % is ranked worse than
54.43% of 1038 companies
in the Biotechnology industry
Industry Median: -141.315 vs NKTR: -188.25

Nektar Therapeutics FCF Margin % Historical Data

The historical data trend for Nektar Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics FCF Margin % Chart

Nektar Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-309.70

-209.62

-419.65

-336.41

-214.68

Nektar Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
FCF Margin %	Get a 7-Day Free Trial															-252.13	-174.59	-197.97	-222.03	-161.30

Competitive Comparison of Nektar Therapeutics's FCF Margin %

For the Biotechnology subindustry, Nektar Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nektar Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's FCF Margin % falls into.

Nektar Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Nektar Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-193.471	/	90.122
	=	-214.68 %

Nektar Therapeutics's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-37.888	/	23.489
	=	-161.30 %

Nektar Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nektar Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (NAS:NKTR) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

0UNL:UK ITH:Germany ITH:Germany

Address

455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158

Website

https://www.nektar.com

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

Executives

Howard W Robin	director, officer: President & CEO
Jonathan Zalevsky	officer: Chief R&D Officer	455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158
Mark Andrew Wilson	officer: SVP & General Counsel	1613 RAY DRIVE, BURLINGAME CA 94010
Robert Chess	director, officer: Executive Chairman
Myriam Curet	director	1020 KIFER ROAD, SUNNYVALE CA 94086
Jeffrey Robert Ajer	director	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Sandra A. Gardiner	officer: Chief Financial Officer	CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Jillian B. Thomsen	officer: VP & Chief Accounting Officer	C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Karin Eastham	director	C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037
Gil M Labrucherie	officer: SVP, COO & CFO	150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
John Northcott	officer: SVP & Chief Commercial Officer	455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158
Diana Brainard	director	C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
R Scott Greer	director	6207 E. INDIAN BEND RD, PARADISE VALLEY AZ 85253
Lutz Lingnau	director	15 INDIAN HOLLOW ROAD, MENDHAM NJ 07945
Stephen K Doberstein	officer: Chief Scientific Officer	129 ELSIE STREET, SAN FRANCISCO CA 94110